Study S000444

Pharmacogenomics of GLP1 Receptor Agonists

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)Informed Consent Form (PDF)

Registration

Registration: NCT05762744
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: SINGLE
Status: TERMINATED
Enrollment: 63
Start: 2016-06-01
Primary completion: 2018-11-30
Lead sponsor: University of Maryland, Baltimore
Conditions: Type 2 Diabetes
Interventions: DRUG:Exenatide Injection (before the first FSIGT); DRUG:Exenatide injection before the second FSIGT)
Results posted: TRUE
Individual participant data sharing: YES

Registered primary outcomes

Exenatide Effect on First Phase Insulin Secretion [0-10 minutes]
Exenatide Effect on Glucose Disappearance Rate [25-50 minutes]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0005987	Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness. Taylor SI, medRxiv : the preprint server for health sciences	2023	Other	PMID 36993363 DOI	cites ClinicalTrials.gov:NCT05762744